Clinical development failure
Pipeline value depends on trial results for Ropidoxuridine and related candidates.
- Scope
- Lead oncology program
- Materiality
- high
Shuttle Pharmaceuticals Holdings, Inc.
Shuttle Pharmaceuticals Holdings, Inc. is a U.S.-based discovery and development stage pharmaceutical company focused on novel cancer therapies. The company’s work centers on product candidates designed to improve the effectiveness and delivery of radiation therapy and related oncology treatments.
0.06
0.06
| % | |
|---|---|
| Oncology drug candidates | 100% Investigational pharmaceutical products designed to treat cancer and improve standard therapies. |
| Radiation therapy enhancement | 0% Compounds intended to improve the safety, reliability, or effectiveness of radiation treatment. |
| Clinical development services | 0% Internal development activities supporting preclinical work, trials, and regulatory advancement. |
Shuttle Pharmaceuticals does not sell commercial products broadly; its primary stakeholders are oncology patients...
- Future oncology treatment providersprimary
Hospitals, cancer centers, and radiation oncology practices that would use approved therapies in patient care.
- Clinical trial ecosystemprimary
CROs, trial sites, investigators, and research partners supporting development of Ropidoxuridine and other candidates.
- Regulatory and scientific stakeholderssecondary
FDA and other oversight bodies, plus academic and clinical collaborators that influence approval and evidence generation.
The company is headquartered in the United States and conducts its development activities from a U.S. base...
- •Headquartered in the United States
- •Clinical development and corporate functions are U.S.-based
- •Dependent on U.S. regulatory pathways for lead candidates
- •No country-level revenue disclosure in the provided reports
- •Exposure is concentrated in the U.S. biotech funding and trial ecosystem
The company’s strategy is to advance a cancer-focused pipeline from discovery into clinical testing, with emphasis on...
01
Advance Ropidoxuridine clinical trialsshort-term
Clinical data is the main value driver for a development-stage oncology company.
02
Maintain financing capacityshort-term
Development programs require ongoing external capital before product revenue exists.
03
Position the platform around radiation oncologymedium-term
A focused therapeutic niche can differentiate the pipeline and support partnering.
Shuttle Pharmaceuticals faces the typical risks of a pre-revenue biotech company: clinical failure, regulatory delays,...
Funding and dilution risk
The company has no operating revenue and relies on equity or similar financing.
- Scope
- Corporate liquidity and development budget
- Materiality
- high
Regulatory approval risk
Drug candidates must satisfy safety and efficacy requirements before commercialization.
- Scope
- FDA and clinical pathway
- Materiality
- high
Third-party execution risk
Trials depend on CROs, clinical sites, and vendors outside direct control.
- Scope
- Theradex and other service providers
- Materiality
- medium
Research and development expense
Higher trial activity increases reported R&D expense
Fair value of convertible notes
Can materially affect net loss and comparability
Derivative financial instruments
Can cause volatility in other expense
Stock-based compensation
Raises reported expenses without immediate cash outflow
MUSTANG BIO, INC.
MBIO · Pharmaceutical Preparations
RAPT Therapeutics, Inc.
Pharmaceutical Preparations
Ocean Biomedical, Inc.
OCEA · Pharmaceutical Preparations
INTENSITY THERAPEUTICS, INC.
INTS · Biological Products, (No Diagnostic Substances)
GT Biopharma, Inc.
GTBP · Pharmaceutical Preparations
Cadrenal Therapeutics, Inc.
CVKD · Pharmaceutical Preparations
: 29/04/2026